In a regulatory filing, Hologic (NASDAQ:HOLX) says that its financial outlook for FQ3 has improved since April 29.
Since then, the Company’s Breast and Skeletal
businesses have performed in line with expectations, and the Surgical
business has begun to recover more rapidly than forecast.
The company forecasts FQ3 Diagnostics revenue to
grow 20-25% (Y/Y), Breast and Skeletal Health revenue to decline 30-35%
and Surgical revenue to decline 65-70%.
HOLX says that the pandemic remain highly uncertain, and therefore cannot quantify the longer-term financial effects.
https://seekingalpha.com/news/3581553-hologic-expects-improved-financial-outlook-for-fiscal-third-quarter
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.